Heart valve tissue engineering: Research should proceed along validated routes

Marco, Francesca di; Gerosa, Gino

doi:10.1016/j.jtcvs.2007.10.075

Cited by 2 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Moreover, extractables obtained from PGG-fixed tissues exhibited low in vitro cytotoxicity toward fibroblasts and smooth muscle cells 41 and thus can be used safely in tissue-engineering applications. [42][43][44][45][46] In current studies, we have shown that PGG binds strongly to pericardial collagen and that this binding is stable for at least 3 weeks in vivo.…”

mentioning

confidence: 54%

Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering

Tedder

Liao

Weed

et al. 2009

Tissue Engineering Part A

123

111

View full text Add to dashboard Cite

Scaffolds for heart valve tissue engineering must function immediately after implantation but also need to tolerate cell infiltration and gradual remodeling. We hypothesized that moderately cross-linked collagen scaffolds would fulfill these requirements. To test our hypothesis, scaffolds prepared from decellularized porcine pericardium were treated with penta-galloyl glucose (PGG), a collagen-binding polyphenol, and tested for biodegradation, biaxial mechanical properties, and in vivo biocompatibility. For controls, we used un-cross-linked scaffolds and glutaraldehyde-treated scaffolds. Results confirmed complete pericardium decellularization and the ability of scaffolds to encourage fibroblast chemotaxis and to aid in creation of anatomically correct valve-shaped constructs. Glutaraldehyde cross-linking fully stabilized collagen but did not allow for tissue remodeling and calcified when implanted subdermally in rats. PGG-treated collagen was initially resistant to collagenase and then degraded gradually, indicating partial stabilization. Moreover, PGG-treated pericardium exhibited excellent biaxial mechanical properties, did not calcify in vivo, and supported infiltration by host fibroblasts and subsequent matrix remodeling. In conclusion, PGG-treated acellular pericardium is a promising scaffold for heart valve tissue engineering.

show abstract

mentioning

confidence: 54%

Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering

Tedder

Liao

Weed

et al. 2009

Tissue Engineering Part A

123

111

View full text Add to dashboard Cite

show abstract

“…The primary modes of heart valve fabrication have been constructs made via polymerization of biosynthetic material, decellularized xeno and allografts, and biodegradable scaffolds [1,[6][7][8][28][29].…”

Section: In Vitro Modeling and Fabricationmentioning

confidence: 99%

“…Heart valve tissue engineering has captured the popular imagination of investigators and patients alike. Expectation and hope is however countered by realistic and legitimate concerns [1][2][3][4][5][6][7][8][9]. The fundamental objective is extension of life expectancy.…”

Section: Introductionmentioning

confidence: 99%

“…Traditional surgical replacement takes the form of mechanical or biological valves [3]. Thromboembolic complications, the need for anticoagulation therapy, sub-optimal hemodynamic performance and prosthetic endocarditis [1][2][3][4][5][6][7][8][9][10][11] are a drawback to mechanical valves. Durability, deterioration, and the absence of growth which necessitates re-replacement is an issue for non-living biological valves [1][2][3][4][5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…This is especially true for congenital heart malformations in pediatric patients [14]. Tissue-engineered heart valves (TEHV) have emerged in recent years as a viable and logical treatment modality to meet this demand [1][2][3][4][5][6][7][8][9][10][11][13][14]. Tissue engineered pulmonary valves (TEPV) have been tested as a replacement valve in defective pulmonary valve (PV) outflow track models [15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bone marrow mesenchymal stem cells for tissue engineered pulmonary valves (TEPV)

Asumda¹,

Lamin²

2014

J Regen Med Tissue Eng

View full text Add to dashboard Cite

Heart valve tissue engineering and regeneration represents a novel, and viable alternative treatment modality for valvular heart disease. Tissue-engineered pulmonary valves (TEPV) have been constructed from autologous cells grown on 3D biodegradable scaffolds or decelluarized xeno-or homografts and surgically implanted in animal models. From a translational stand point, constructed valves must maintain regenerative competency in recipients, with minimum risk for stenosis over the long term. Stem cells are an attractive cell source for this proposed solution; candidate cells are expected to maintain robust differentiation and transdifferentiation capacity. Transplanted cells must persist, engraft, and couple electro-mechanically with endogenous tissue. Here, we present a discussion on the clinical applicability of bone marrow mesenchymal stem cells in TEPV.

show abstract

Heart valve tissue engineering: Research should proceed along validated routes

Abstract: Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material.

Cited by 2 publications

References 3 publications

Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering

Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering

Bone marrow mesenchymal stem cells for tissue engineered pulmonary valves (TEPV)

Contact Info

Product

Resources

About